Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Total Current Liabilities (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed Total Current Liabilities for 4 consecutive years, with $2.9 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities fell 6.4% to $2.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.9 million through Dec 2025, down 6.4% year-over-year, with the annual reading at $2.9 million for FY2025, 6.4% down from the prior year.
  • Total Current Liabilities for Q4 2025 was $2.9 million at bioAffinity Technologies, up from $2.4 million in the prior quarter.
  • The five-year high for Total Current Liabilities was $3.4 million in Q1 2025, with the low at $775151.0 in Q2 2023.
  • Average Total Current Liabilities over 4 years is $2.1 million, with a median of $2.3 million recorded in 2023.
  • The sharpest move saw Total Current Liabilities skyrocketed 200.11% in 2024, then decreased 6.4% in 2025.
  • Over 4 years, Total Current Liabilities stood at $1.1 million in 2022, then skyrocketed by 97.41% to $2.2 million in 2023, then surged by 38.13% to $3.1 million in 2024, then decreased by 6.4% to $2.9 million in 2025.
  • According to Business Quant data, Total Current Liabilities over the past three periods came in at $2.9 million, $2.4 million, and $2.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.